Testing a single-probe liver exam for chronic disease
Part of Digestive system clinical trials.
This study is testing a new way to use a FibroScan (a non-invasive liver scanner) with a single probe to measure liver health in people with chronic liver disease. If you have a long-term liver condition, this trial may help improve how liver exams are done.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a long-term liver problem (chronic liver disease).
- You should be able to understand and sign the consent form.
- If you are in a European country, you must have health insurance or be covered by the healthcare system.
- You cannot have fluid in your belly (ascites), heart failure, sudden hepatitis, or a blocked bile duct.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
This study tests a new, non-invasive way to measure liver stiffness using a device called FibroScan. It aims to make liver checkups easier and more comfortable for people with liver disease.
This trial looks at tiny particles in the blood (extracellular vesicles) to see if they can help doctors understand and track liver disease. It includes healthy volunteers, people with diabetes and liver scarring, and people with cirrhosis, with the goal of finding better biomarkers.
This trial uses a blood test (FIB-4) to find liver scarring (fibrosis) in people who haven't been tested before. It aims to catch advanced liver disease early, which can help you get treatment sooner.
This study looks at whether a city-hospital partnership can help find liver fibrosis (early scarring of the liver) earlier in people who get a Fibroscan test ordered by their primary care doctor. It is for adults whose Fibroscan result was at least 8 kPa and who had the test between 2023 and 2026.
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
Hear when a new Liver Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.